Frederic Roch Doliveux
Fortune : 4 M $ au 31/05/2026
Fortune : 4 M $ au 31/05/2026
Le Dr Frederic Roch Doliveux est président non exécutif d'Oxford Biomedica Plc, président du Caring Entrepreneurship Fund, président de Pierre Fabre SA et membre du Conseil international de l'INSEAD. Il est membre du conseil d'administration d'UCB SA, de la Vlerick Leuven Gent Management School, de Vlerick Research NV, de la Biotechnology Innovation Organization, de Pierre Fabre Participations SASU, du Science & Business Innovation Board et du Wallon Institute for Life Lead Sciences. Le Dr Doliveux a été précédemment employé en tant que président par GLG Healthcare Institute, directeur indépendant par Stryker Corp, directeur général et directeur exécutif par UCB SA, président par Schering-Plough Corp, président par Schering-Plough International, Inc, vice-président par European Federation of Pharmaceutical Industries & Assns, directeur général par Pierre Fabre Pharmaceuticals, Inc, et président par The Innovative Medicines Initiative. Il est titulaire d'un MBA de l'INSEAD et d'un doctorat de l'École Nationale Vtrinaire d'Alfort.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OXFORD BIOMEDICA PLC 0,36 % | 31/12/2025 | 438 805 ( 0,36 % ) | 4 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| OXFORD BIOMEDICA PLC | Président | 24/06/2020 |
Vlerick Research NV
Vlerick Research NV Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Directeur/Membre du Conseil | 01/11/2012 |
Pierre Fabre Participations SAS
Pierre Fabre Participations SAS Pharmaceuticals: MajorHealth Technology Manufactures and distributes dermatology and cosmetic products | Directeur/Membre du Conseil | 24/07/2019 |
Caring Entrepreneurship Fund | Président | 01/01/2009 |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Directeur/Membre du Conseil | - |
Wallon Institute for Life Lead Sciences | Directeur/Membre du Conseil | 14/09/2010 |
Science & Business Innovation Board | Directeur/Membre du Conseil | 14/09/2010 |
INSEAD International Council | Corporate Officer/Principal | 15/03/2012 |
Pierre Fabre SA
Pierre Fabre SA BiotechnologyHealth Technology Engages in research and preclinical development of biologics & pharmaceuticals | Président | 01/05/2017 |
| ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░ ░░░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░ ░░░░ ░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 22 |
|---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceutical & health care products | Health Technology |
Stryker Corp.
Stryker Corp. Medical SpecialtiesHealth Technology Manufactures and markets reconstructive, medical and surgical, and neurotechnology and spine products | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
UCB SA
UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
Oxford Biomedica Plc
Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
Pierre Fabre SA
Pierre Fabre SA BiotechnologyHealth Technology Engages in research and preclinical development of biologics & pharmaceuticals | Health Technology |
Pierre Fabre Participations SAS
Pierre Fabre Participations SAS Pharmaceuticals: MajorHealth Technology Manufactures and distributes dermatology and cosmetic products | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
INSEAD
INSEAD Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vlerick Leuven Gent Management School
Vlerick Leuven Gent Management School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
European Federation of Pharmaceutical Industries & Assns
European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services Operates as a trade association which promotes pharmaceutical discovery and development | Commercial Services |
Chiesi Ltd.
Chiesi Ltd. Pharmaceuticals: MajorHealth Technology Develops, markets and supplies therapeutic products | Health Technology |
École Nationale Vétérinaire d'Alfort
École Nationale Vétérinaire d'Alfort Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
INSEAD International Council | |
Science & Business Innovation Board | |
Wallon Institute for Life Lead Sciences | |
The Innovative Medicines Initiative
The Innovative Medicines Initiative Drugstore ChainsRetail Trade Operates as pharmaceutical industry | Retail Trade |
Schering-Plough International, Inc.
Schering-Plough International, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells pharmaceuticals and health care products | Health Technology |
Caring Entrepreneurship Fund | |
GLG Healthcare Institute
GLG Healthcare Institute Medical/Nursing ServicesHealth Services Provides health care services | Health Services |
Vlerick Research NV
Vlerick Research NV Miscellaneous Commercial ServicesCommercial Services Provides research and development services | Commercial Services |
Pierre Fabre Pharmaceuticals, Inc.
Pierre Fabre Pharmaceuticals, Inc. Medical DistributorsDistribution Services Part of Pierre Fabre Participations SAS, Pierre Fabre Pharmaceuticals, Inc. is a company that offers Hemangeol, an FDA-approved oral propranolol hydrochloride solution formulated to treat proliferating infantile hemangioma, a common benign vascular tumor in infants that may require systemic therapy to prevent complications affecting vision, breathing, or feeding. The company is based in Parsippany, NJ. The product is designed for infants, featuring a strawberry-vanilla flavor and is free of alcohol, sugar, and parabens, and is supplied with a child-resistant dosing syringe. Treatment typically begins between 5 weeks and 5 months of age and continues for about six months, with weight-based dosing administered twice daily during or after feeding. Safety information includes contraindications such as premature infants under five weeks corrected age, low body weight, asthma, certain cardiac conditions, and propranolol allergy, with potential side effects including hypoglycemia, bradycardia, hypotension, bronchospasm, cardiac failure, increased stroke risk in certain conditions, and hypersensitivity reactions. Common side effects are sleep disturbances, respiratory infections, diarrhea, and vomiting. The product includes dosing charts, calculators, and caregiver support tools to assist with treatment adherence and monitoring. Pierre Fabre Pharmaceuticals provides resources for healthcare professionals, pharmacists, and caregivers, including prescribing information, safety guidelines, educational materials, and patient assistance programs, and collaborates with patient advocacy groups to enhance education and support for families managing infantile hemangiomas. | Distribution Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national